MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Development and Validation of Personal Technology to Treat Hypophonia in Patients with Parkinson’s Disease

A. Klein, A. Gillespie, D. Anderson, M. Caveney, N. Sundholm (Atlanta, USA)

Meeting: 2025 International Congress

Keywords: Parkinson’s, Voice tremor

Category: Parkinson’s Disease: Clinical Trials

Objective: The purpose of this study was to develop and validate wearable technology to improve vocal intensity in patients with Parkinson’s Disease.

Background: Parkinson’s disease (PD) severely impacts communication in 70-90% of patients. Behavioral voice therapy can be effective in Parkinson’s-related voice and speech disorders by increasing vocal loudness and improving speech intelligibility. However, success in treatment is dependent on an intensive intervention schedule. This treatment burden, combined with reduced ability of patients with Parkinson’s to self-monitor voice leads to a high rate of symptomatic relapse following treatment.

Method: Our multi-disciplinary, multi-institutional team created a low-profile headset device that can isolate, monitor, and analyze vocal output for time and loudness and provide haptic biofeedback in the form of vibration to the wearer when minimum threshold intensity targets are not met. In this study, we tested the device in 8 patients with PD during a 60-minute treatment session. Each session consisted of 30 minutes with and 30 minutes without speech pathologist’s feedback on vocal intensity. Intensity change and time between cues to increase intensity were measured and analyzed for differences between baseline and each condition.

Results: There were no significant differences (p = 0.25) in time between cues to increase intensity in the SLP assisted condition compared to the device condition. There was no significant difference for change in vocal intensity in decibels between the SLP assisted condition and the device assisted condition (p = 0.66). When groups were split by disease severity, those with mild to moderate PD required significantly fewer intensity cues and increased vocal intensity significantly more than those with severe PD for both the SLP and device-assisted conditions (p<.001).

Conclusion: Patients with mild to moderate PD respond positively to the haptic feedback provided by an individually calibrated low profile headset. This technology may serve as a helpful adjunct to standard-of-care voice therapy. Current studies are investigating if the addition of the device in voice therapy improves outcomes including a reduction in treatment time and relapse.

Fig 1: human subject wearing SAMMS device

Fig 1: human subject wearing SAMMS device

To cite this abstract in AMA style:

A. Klein, A. Gillespie, D. Anderson, M. Caveney, N. Sundholm. Development and Validation of Personal Technology to Treat Hypophonia in Patients with Parkinson’s Disease [abstract]. Mov Disord. 2025; 40 (suppl 1). https://www.mdsabstracts.org/abstract/development-and-validation-of-personal-technology-to-treat-hypophonia-in-patients-with-parkinsons-disease/. Accessed October 5, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2025 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/development-and-validation-of-personal-technology-to-treat-hypophonia-in-patients-with-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Insulin dependent diabetes and hand tremor
  • Improvement in hand tremor following carpal tunnel release surgery
  • Impact of expiratory muscle strength training (EMST) on phonatory performance in Parkinson's patients
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley